EGFR and non-small cell lung carcinoma: In the present study, we investigated the therapeutic outcomes of NSCLC patients harboring uncommon EGFR mutations other than 20ins and T790M who received first-line therapy of gefitinib/erlotinib/icotinib and afatinib.